Our Investors
Our investors share our visions and passions
Our investors share our vision and passion and bring deep expertise and experience in developing promising companies such as Artios.
Artios raised $153 million (£110 million) in July 2021 in a Series C financing. The financing was oversubscribed and was led by Omega Funds and TCG X. Our new investors are Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments LP, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital.
These new investors join existing investors Arix Bioscience plc, SV Health Investors, Andera Partners, LSP (Life Sciences Partners), M Ventures, Pfizer Ventures, IP Group plc, and Novartis Venture Fund who also continue to support Artios through their participation.
In connection with the close of the Series C financing, Michelle Doig, Partner, Head of Corporate Development, Omega Funds and Chen Yu, Founding Managing Partner, TCG X, joined Artios’ Board of Directors.
In August 2018, Artios raised $84 million (£65 million) in a Series B financing. The financing was oversubscribed and was led by Andera Partners and LSP, with participation by additional new investors Pfizer Ventures and Novartis Bioventures. Existing shareholders AbbVie Ventures, Arix Bioscience, IP Group, Merck Ventures and SV Health Investors also participated in the fundraise.
This financing follows a $33 million (£25 million) Series A fundraise that was completed in September 2016.
